eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2024
vol. 21
 
Share:
Send email
Share:
Review paper

Pulmonary embolism in cancer patients. Effectiveness of vitamin K antagonists and direct oral anticoagulants in long-term therapy

Paulina M. Nadziakiewicz
1
,
Bożena Szyguła-Jurkiewicz
2

  1. Student’s Scientific Society, 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
  2. 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
Kardiochirurgia i Torakochirurgia Polska 2024; 21 (2): 102-107
DOI: https://doi.org/10.5114/kitp.2024.141148
Online publish date: 2024/07/07
Article file
- Pulmonary embolism.pdf  [0.14 MB]
Get citation
 
PlumX metrics:
 
1. Shatla I, El Iskandarani M, Munir M, Khan M. Sex differences in outcomes among patients hospitalized with pulmonary embolism: insights from National Inpatient Sample 2002-2020. Eur Heart J 2023; 44 (Suppl 2). doi:10.1093/eurheartj/ehad655.1988
2. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 2013; 18: 129-138.
3. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemostasis 2011; 9: 316-324.
4. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich Jr J, Hobbins TE. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
5. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122: 1712-1723.
6. Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, Ayoub E, Duvillard C, Accassat S, Mismetti P, Heestermans M, Bertoletti L. Pulmonary embolism in the cancer associated thrombosis landscape. J Clin Med 2022; 11: 5650.
7. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 suppl 1): I4-8.
8. Cai B, Bedayat A, George E, Hunsaker AR, Dill KE, Rybicki FJ, Kumamaru KK. Malignancy and acute pulmonary embolism. J Thorac Imaging 2013; 28: 196-201.
9. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. findings from the RIETE Registry. Thromb Res 2013; 131: 24-30.
10. Pietrasik A, Gąsecka A, Kurzyna P, Smyk JM, Wasilewski M, Wolański R, Wrona K, Darocha S, Zieliński D, Grabowski M, Torbicki A, Kurzyna M. Cancer-associated thrombosis: comparison of characteristics, treatment, and outcomes in oncological and non-oncological patients followed by pulmonary embolism response team. Pol Arch Intern Med 2023; 133: 16421.
11. Pietrasik A, Gąsecka A, Kurzyna P, Wrona K, Darocha S, Banaszkiewicz M, Zieliński D, Zajkowska D Smyk JM, Rymaszewska D, Jasińska K, Wasilew- ski M, Wolański R, Procyk G, Szwed P, Florczyk M, Wróbel K, Grabow- ski M, Torbicki A, Kurzyna M. Characteristics and outcomes of patients consulted by a multidisciplinary pulmonary embolism response team: 5-year experience. J Clin Med 2022; 11: 3812.
12. Erythropoulou-Kaltsidou A, Alkagiet S, Tziomalos K. New guidelines for the diagnosis and management of pulmonary embolism: key changes. World J Cardiol 2020; 12: 161-166.
13. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
14. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis. J Thromb Haemostasis 2014; 12: 320-328.
15. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2013; 53: 1-16.
16. Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol 2020; 86: 533-547.
17. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
18. Deaton JG, Nappe TM. Warfarin Toxicity. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431112/
19. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest 2017; 151: 127-138.
20. Martini A, Harenberg J, Bauersachs R, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Weiss C, Hetjens S. Detection of direct oral anticoagulants in patient urine samples by prototype and commercial test strips for DOACs – a systematic review and meta-analysis. TH Open 2021; 5: e438-e448.
21. van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J 2023; 44: 1795-1806.
22. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
23. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
24. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
25. Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005; 19: 197-201.
26. Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, Védri- ne L, Bensalha H, Bonnet I, Péré-Vergé D, Coudurier M, Li V, Rafii H, Benzi-dia I, Connors JM, Resche-Rigon M. Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: The QUAVITEC study on behalf of the groupe francophone thrombose et cancer (GFTC). Oncotarget 2018; 9: 26990-26999.
27. Bleker SM, Brekelmans MPA, Eerenberg E, Cohen A, Middeldorp S, Raskob G, Büller HR. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor XA inhibitors or vitamin K antagonists. Thromb Haemostasis 2017; 117: 1944-1951.
28. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lan- keit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Prusz- czyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2019; 41: 543-603.
29. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler- Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Leni- han D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamar­go J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-4361.
30. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Gros- so MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624.
31. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (select-D). J Clin Oncol 2018; 36: 2017-2023.
32. McBane RD, Wysokinski WE, Le-Rademacher J. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. Blood 2018; 132 (Suppl 1): 421.
33. Agnelli G, Becattini C, Meyer G, Muńoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gusso- ni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607.
34. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res 2020; 185: 13-19.
35. Leszek P, Klotzka A, Bartuś S, Burchardt P, Czarnecka AM, Długosz-Danecka M, Gierlotka M, Koseła-Paterczyk H, Krawczyk-Ożóg A, Kubiatowski T, Kurzyna M, Maciejczyk A, Mitkowski P, Prejbisz A, Rutkowski P, Sierko E, Sterliński M, Szmit S, Szwiec M, Tajstra M, Tycińska A, Witkowski A, Wojakowski W, Cybulska-Stopa B. A practical approach to the 2022 ESC Cardio-Oncology Guidelines: Comments by a team of experts – cardiologists and oncologists. Kardiol Pol 2023; 81: 1047-1063.
36. Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, Hodge DO, Peterson LG, Mcbane RD. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 2019; 94: 1185-1192.
37. Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meverden RA, Hodge DO, Peterson LG, McBane RD, Wysokinski WE. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Mayo Clin Proc 2021; 96: 2793-2805.
38. Caroti KS, Becattini C, Carrier M, Cohen AT, Ekbom A, Khorana AA, Lee AYY, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding. TH Open 2023; 7: e206-e216.
39. Tsoukalas N, Tsapakidis K, Galanopoulos M, Karamitrousis E, Kamposioras K, Tolia M. Real World Data regarding the management of cancer-associated thrombosis. Curr Opin Oncol 2020; 32: 289-294.
40. Guo JD, Hlavacek P, Poretta T, Wygant G, Lane D, Gorritz M, Wang X, Chen CC, Wade RL, Pan X, Rajpura J, Stwalley B, Rosenblatt L. Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. J Thromb Thrombolysis 2020; 50: 386-394.
41. Riaz IB, Fuentes H, Deng Y, Naqvi SAA, Yao X, Sangaralingham LR, Hou- ghton DE, Padrnos LJ, Shamoun FE, Wysokinski WE, McBane 2nd RD. Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Network Open 2023; 6: e232583.
Copyright: © 2024 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.